$ANNX News

Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7

Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate

Annexon Q4 EPS $(0.28) Beats $(0.32) Estimate

Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Annexon Highlights 2026 Milestones With Tanruprubart MAA Filing, Vonaprument Phase 3 Data In Dry AMD, ANX1502 Proof‑of‑Concept Readout, Snd Strong Cash Position Funding Into 2027

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome

Chardan Capital Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $16

Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

With Annexon Up 14%, Insider Buyers Count Their Returns

Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17

Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Annexon shares are trading higher after Wells Fargo maintained the stock with an Overweight rating and raised its price target from $14 to $27.

Annexon shares are trading higher after Wells Fargo maintained the stock with an Overweight rating and raised its price target from $14 to $27.